Research
Hormonal
Tirzepatide is a broadly acceptable and preferred long-term treatment for comorbid obesity and obstructive sleep apnea (COBOSA) by patients, offering efficacy comparable to CPAP with different adherence profiles.
If you have obesity and sleep apnea, tirzepatide is a valid, once-weekly treatment option that many patients prefer over CPAP. Discuss with your doctor if it's right for you, considering factors like cost, side effects, and your preference for injections vs. devices.
ModerateSupportsMEDIUM confidence
When asked to choose a preferred long-term therapy assuming equal effectiveness, patients favored tirzepatide (48% vs 21%), while providers preferred CPAP (52% vs 27%).
Why this rating
Based on a cross-sectional survey of preferences, not a comparative efficacy trial.
Source
Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide
Christopher N. Schmickl et al. · medRxiv · 2025
DOI 10.1101/2025.10.02.25337176
preprint · n=575
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →